FGFR2 and cholangiocarcinoma: Recent data from Arai et al., indicate that FGFR2 fusion genes occur in 13.6% of intrahepatic CCA cases; Borad et al. have described responses to targeted FGFR inhibitors in this patient subgroup [35], [36].